8-K
filed June 15, 2026, 6:23 AM ET
ticker FLNA
CIK 0001069530
other material
confidence high
sentiment neutral
materiality 0.50
Filana shareholders approve 2018 Omnibus Incentive Plan amendment; authorized shares increased to 9M
FILANA THERAPEUTICS, INC.
- Shareholders approved Amendment No. 2 to the 2018 Omnibus Incentive Plan, increasing authorized shares from 5M to 9M (4M added).
- Plan term extended through January 31, 2030; repricing of options/SARs explicitly prohibited without stockholder approval.
- Three directors elected: Richard J. Barry, Pierre Gravier, Claude Nicaise, M.D. (each ~8.9M for, ~1.5M withheld, ~14.1M broker non-votes).
- Ernst & Young ratified as auditor for FY2026 (22.7M for, 1.4M against). Non-binding say-on-pay passed (7.5M for, 2.8M against).
- 51% of outstanding shares (24.6M of 48.3M) represented at the meeting, constituting a quorum.
Key facts
Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.95
FILANA THERAPEUTICS, INC. shareholders approved Amendment to the 2018 Omnibus Incentive Plan at the 2026-06-11 meeting.
- Proposal
- equity plan
- Outcome
- passed
- Meeting
- 2026-06-11
Exact text from the filing
Proposal Two – An amendment to the Company’s 2018 Omnibus Incentive Plan was approved based upon the following votes: For Against Abstain Broker Non -Vote 8,427,565 1,869,290 118,621 14,144,300
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.95
FILANA THERAPEUTICS, INC. shareholders approved Election of three nominees to the Board of Directors at the 2026-06-11 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2026-06-11
Exact text from the filing
Proposal One – Three (3) nominees for election or re-election to the Board of Directors were elected to serve for a three-year term, and until their successors are duly elected and qualified, based upon the following votes: Director For Withheld Broker Non-Vote Richard J. Barry 8,851,285 1,564,191 14,144,300 Pierre Gravier 9,069,595 1,345,881 14,144,300 Claude Nicaise, M.D. 8,924,355 1,491,121 14,144,300
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.95
FILANA THERAPEUTICS, INC. shareholders approved Ratification of appointment of Ernst & Young LLP as independent registered public accounting firm at the 2026-06-11 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2026-06-11
Exact text from the filing
Proposal Three – The appointment of Ernst & Young LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2026, was ratified based upon the following votes: For Against Abstain 22,671,610 1,408,513 479,653
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.95
FILANA THERAPEUTICS, INC. shareholders approved Advisory vote on executive compensation at the 2026-06-11 meeting.
- Proposal
- say on pay
- Outcome
- passed
- Meeting
- 2026-06-11
Exact text from the filing
Proposal Four – The 2025 executive compensation for the Company’s named executive officers was approved, on a non-binding advisory vote, based upon the following votes: For Against Abstain Broker Non -Vote 7,487,142 2,827,840 100,494 14,144,300
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.